

Check list of issues that may be covered during plenary discussions

1) Session II – Discussion – implementation challenges (Marietjie Venter)

- a. Implementation challenges at level of sentinel sites
 - i. Adapting the case definition
 - ii. Algorithm for selection of patients for testing for RSV
 - iii. Attaining sample size for 0-6m, 6m-5y and 65+y age group
 - iv. Year-round sampling
 - v. Transporting specimens to laboratory
 - vi. Collection of clinical data
 - vii. Acceptance of RSV surveillance by sentinel physicians
 - viii. Impact of RSV testing on SARI, ILI surveillance
 - ix. Any other challenge
- b. Implementation challenges at level of laboratory
 - i. EQAP
 - ii. Supply of primers, probes, reagents, enzymes etc.
 - iii. Algorithm for selection of specimens for RSV testing
 - iv. Any other challenge
- c. Implementation challenges at level of data management
 - i. Timeliness, completeness and transfer of clinical data from sentinel site to laboratory
 - ii. Integration of clinical and laboratory data
 - iii. Uploading onto FluMart
 - iv. Acceptance by laboratory staff and impact of RSV testing on influenza

2) Session VIII – Plenary discussion – final products of pilot (Harish Nair)

- a. List of final products
 - i. RSV surveillance strategy – case definition, high risk groups, optimal size, all-year round testing, etc.
 - ii. Standardized laboratory protocol for RT-PCR for RSV
 - iii. Need for RSV typing, RSV sequencing
 - iv. Incremental costs for RSV surveillance based on GISRS, etc.
- b. Data and analysis needed for these products
- c. Analysis end-points, stratification, variables required
- d. Data gaps and ways to bridge gap

3) Session VIII – Plenary discussion – sustainability (Peter Smith)

- a. What would be the “minimum size” and “optimal size” of the surveillance – no. of sentinel sites, priority for hospital or community based surveillance, target groups, minimum sample size, year-round or seasonal sampling, etc.
- b. Is there a need for case-based clinical data beyond the pilot?
- c. What internal or national resources are available to offset the incremental costs?
- d. What needs to be done to institutionalize and integrate RSV surveillance with GISRS?
- e. How can WHO support beyond 2018